Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gene Transfer For Patients With Sickle Cell Disease Using A Gamma Globin Lentivirus Vector: An Open-Label Phase 1 / 2 Pilot Study

Next Previous
Search
Trial Profile

Gene Transfer For Patients With Sickle Cell Disease Using A Gamma Globin Lentivirus Vector: An Open-Label Phase 1 / 2 Pilot Study

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARU 1801 (Primary) ; Melphalan
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MOMENTUM

    • Most Recent Events

    • 05 Apr 2024 Status changed from active, no longer recruiting to discontinued.
    • 18 Jul 2023 Planned End Date changed from 1 Jun 2035 to 1 Jul 2038.
    • 18 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 14 Jul 2037.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top